Member Info for inanaco

BioNTech said today it agreed to acquire the operational antibody generation unit of MAB Discovery for an undisclosed price, in a deal that builds on two collaborations by the companies stretching back nearly six years.

funny how they use Collaboration before making a move ..

what do we need £30m for ?

you get the point Ray .. it's convincing the market ...

difficult to find .... they are not found on all patients .................

look at Modi1 again ........

Vimentin and enolase targets are highly expressed in triple negative breast cancer (90%), ovarian
cancer (95%), and osteosarcoma (100%)

which is why you cannot compare like with like ... so in this instance Roche is taking a punt of a $100m upfront against extremely low numbers .. ie lung only 19 to 35%

Industry identifies weak targets ... because that is all they can find ... remember the big failure of the GSK Mage Vaccine ... has anyone looked at the research behind it that is even today still ongoing ..

Over an "antigen" ......

https://www.nature.com/articles/srep25182

Of note, the percentage of MAGE-A4-positive patient tumors observed in select cancer subtypes has been reported as follows: 47% in ovarian cancers, 19–35% in lung cancers, 22% in colon cancers and 13% in breast cancers39. The role of MAGE-A4 in cancers is not fully understood especially at macromolecular level.

http://www.pmlive.com/pharma_news/roche_builds_on_immunocore_immtac_deal_1261125

can you see the problem they face .... ???

You can have the greatest Car T system in the world
You can have the Greatest TCR system in the world
You can have the most efficient vaccine in the world

but all these processes need one thing ... A Target or multiple Targets to lock onto ...

the Epitope ... that tiny signal that the immune system can see that identifies the cancer as foreign

then you need a system that can break through the cancers ability to create an immunosuppressive environment

...

Don't forget ISA Pharma in all this .. they have a commercial interest in Modi1

what is the odds ?

Ruckrover

you almost gloat in the fact they didn't win it, yet your last buy was at 10.4p .. not quite sure what you are trying to achieve .. ?

we expected to win !! .... otherwise why would Scancell apply if they expected to lose ... ?

your posts make no sense in the real world ... every game has winners and losers ... and teams at the bottom of the league get cheered and people still buy tickets even when they are expected to lose ... !! But we are not bottom .. we came out in the top 10 from 140 ...

so i would describe your style as pontificating ...

One other point that has maybe not been explained ...

Neo Antigen search .... the industry is making great plays into this field to find personal Neo antigens that are immunogenic but they are looking at the cd4/Cd8 killer cell which is yielding only about 20% efficacy

now what we don't know

""""" alongside vaccines targeting new mutations within individual patient tumours, for the treatment of virtually all cancers. """"

was that a search for """""personal"""" "moditope" epitopes .... ?

its yet another area that can potentially be tapped ...

Like Modi2 ... we only get the finer details like Homocitrulline once the patent applications etc are sorted, so what you see today .. is potentially 12 to 18 months behind the discovery phase so if new potential patents are involved we get this vague RNS a Title with little description ....

non regulatory or not ... that is still significant news ...

Modi3 has not gone away ......

Project Blueprint was devised to investigate the potential of cancer vaccines, based on treatment with Modi-3, a product generated from Scancell's Moditope® platform, alongside vaccines targeting new mutations within individual patient tumours, for the treatment of virtually all cancers.

,"""" based on treatment with Modi-3, a product generated from Scancell's Moditope® platform, """"

that is quite significant to put into RNS

Calm down Mr Ivy ... the SP moved because of the RNS about the way scancell is forging ahead on its existing collaborations and trials by hiring highly skilled staff ...

The sp has sat at this level for a while ...

""" inevitable advance hype and then a steep SP fall like """

Val is not a research company like Scancell ........... its never had a discovery , hardly surprising thou it has no research scientists

Val201 was licensed from CRUK

Scancell continues to be funded to initiate the planned phase 2 clinical study for our lead ImmunoBody®, SCIB1, and to advance our lead Moditope® vaccine, Modi-1, towards the clinic, and this remains our core focus for the immediate future."

Scancell at present are concentrating on existing commitments as per RNS ... why would they need a placing ? Project Blueprint was a 5 year program not a 5 week program ...

and i was looking forward to actually paying some Capital Gains .. oh well transfer again in April

Clearly its already in development .........

"""Project Blueprint was devised to investigate the potential of cancer vaccines, based on treatment with Modi-3, a product generated from Scancell's Moditope® platform """

A product generated !!!

""""Notwithstanding the result of the Award, Scancell and its collaboration partners remain committed to the ultimate objective of eliminating tumours by treating patients with such therapeutic vaccine approaches. """

which is what i posted earlier that the Project may already be Green lighted ...

well we have a fully formed project ... as presented to CRUK .. ... lets see if the commercial instincts of our partners kicks in ..

that requires meetings and consensus ... not going to be RNS tomorrow unless they already had a backup plan